Researchers from Jecho Laboratories Inc. and Shanghai Jiao Tong University reported the discovery of a novel anti-PD-L1/CXCR4 bispecific nanobody, BsNb PX-4, being developed for the treatment of cancer.
Retrotransposons could have a main role in the development of drug resistance in response to cancer treatment, according to a new study out of the Roswell Park Comprehensive Cancer Center. The transposition of DNA elements triggers an inflammatory response involved in the survival of cancer cells, a mechanism that could be blocked applying reverse transcriptase inhibitors, a class of drugs better known as anti-HIV medications.
CSPC Pharmaceutical Group Ltd. has received IND approval from the FDA for a phase I study in the U.S. of its antibody-drug conjugate CPO-204 in patients with locally advanced or metastatic urothelial cancer.
Sotio Biotech AS has exercised its first of five exclusive, target-specific options with Legochem Biosciences Inc. for antibody-drug conjugate (ADC) SOT-106, which is currently being evaluated in preclinical studies in multiple solid tumor indications.
Point Biopharma Global Inc. has released new preclinical data from its pan-cancer fibroblast activation protein-α (FAP-α) targeted program, PNT-2004. The preclinical study focused on assessing the potential of the lead candidate in the PNT-2004 clinical program, [177Lu]PNT-6555, in combination with anti-programmed cell death protein 1 (PD-1) immunotherapy.
Context Therapeutics Inc. has selected CTIM-76, a T cell-engaging bispecific antibody, as its lead clinical development candidate to target Claudin-6 (CLDN6)-positive cancers. Resulting from a research collaboration and licensing agreement with Integral Molecular Inc., CTIM-76 is a CLDN6 x CD3 bispecific antibody that incorporates a highly selective CLDN6 binding arm and a CD3 binding single-chain Fv domain in an IgG format with a silenced Fc that is designed to be functionally monovalent to avoid aberrant T-cell activation and to enhance the safety profile.
Does cancer cause autoimmune disease or is it the other way around? In looking at the question of which comes first, the chicken or the egg, researchers at the Garvan Institute of Medical Research in Australia found that a genetic mutation that alters immune cells in leukemia is behind certain autoimmune disorders.
Taisho Pharmaceutical Co. Ltd. has synthesized sulfonamide-containing peptides acting as MMP-7 (matrilysin) inhibitors reported to be useful for the treatment of cancer.
RSS
